CFO Lawlor Buys $50K in Quoin Private Placement at $4.88
QNRX sits 94% above its 52-week low of $3.25 on light trading volume (0.4× avg).
Summary
CFO Sally Bridget Lawlor bought $49,990.72 of Quoin ADSs and warrants in the company's $50M private placement at $4.88 per ADS, joining Director Culverwell in insider participation.
Key Events · Ownership and Investor Activity · QNRX
-
CFO Buys $50K in Private Placement
Sally Bridget Lawlor acquired 10,244 ADSs and 5,122 warrants for $49,990.72 at $4.88 per ADS on 2026-08-31, the same terms as all investors in the $50M placement.
-
Second Insider Purchase Confirmed
This follows Director Anthony Culverwell's concurrent $29,992 purchase in the same placement, bringing total disclosed insider participation to approximately $80K.
-
Post-Transaction Holdings
Lawlor now directly holds 10,684 ADSs and 5,122 warrants, with warrants exercisable at $6.10 per ADS and expiring in 5 years or 30 days after the Netherton Syndrome trial primary endpoint announcement.
-
Placement Context
The $50M private placement was priced at $4.88/ADS on 2026-08-28, extending Quoin's cash runway as the company reported a wider net loss and going-concern doubt in its Q2 2026 10-Q.
Analysis · QNRX · Life Sciences
CFO Sally Bridget Lawlor purchased 10,244 ADSs and 5,122 warrants for $49,990.72 at $4.88 per ADS in the company's $50M private placement, confirming insider participation alongside Director Culverwell's concurrent $29,992 purchase. The CFO's direct stake now stands at 10,684 ADSs plus 5,122 warrants. This is a meaningful personal investment by the chief financial officer at the same terms as all other investors, reinforcing management's alignment with the capital raise that extends Quoin's cash runway amid its going-concern status.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNRX was trading at $6.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $3.25 to $41.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.